Middleton (10-1) flashed the form that earned him the moniker of Mississippi’s best collegiate baseball this spring, checking ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics ...

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We ...

Scotiabank lowered the firm’s price target on Keros Therapeutics (KROS) to $26 from $41 and keeps an Outperform rating on the shares. The firm is ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...

We've discovered 1 warning sign about Keros Therapeutics. View them for free. Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates significantly.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...